Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | ARQ 531 |
Trade Name | |
Synonyms | ARQ531|ARQ-531|Nemtabrutinib|MK-1026|MK 1026|MK1026 |
Drug Descriptions |
ARQ 531 is an ATP-competitive BTK inhibitor with activity against wild-type BTK and BTK C481S, which may inhibit migration and viability of tumor cells (PMID: 30093506, PMID: 31992353). |
DrugClasses | BTK inhibitor 38 |
CAS Registry Number | 2095393-15-8 |
NCIT ID | C138066 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
ARQ 531 | ARQ 531 | 1 | 4 |
ARQ 531 + Pembrolizumab | ARQ 531 Pembrolizumab | 0 | 1 |
ARQ 531 + Rituximab | ARQ 531 Rituximab | 0 | 1 |
ARQ 531 + Venetoclax | ARQ 531 Venetoclax | 0 | 1 |
ARQ 531 + VLS-101 | ARQ 531 VLS-101 | 0 | 1 |